



Contact:

David Waldman or Natalya Rudman
Crescendo Communications Europe Sp. z o.o.
Email: mmd@crescendo-ir.com

Dom Maklerski WDM S.A.
Email: us@wdmcapital.com
Tel: (+48 71) 79 11 555

Milestone Medical Inc. to Present at 2nd Global Life Sciences Conference in Warsaw

LIVINGSTON, NJ, September 23, 2014 -- Milestone Medical Inc. (WAR: MMD), today announced that Leonard Osser, Chief Executive Officer will present at the upcoming 2nd Global Life Sciences Conference in Warsaw on October 2, 2014 at the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. A recording of the presentation will be posted on Milestone Medical's website following the conference.

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On October 2nd, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Milestone Medical's management through a corporate presentation and small group meetings.

The organizers of this event are: WDM Capital, Wedbush Europe and the Filipex Enterprises. The partners of this event are: Warsaw Stock Exchange, Wedbush, Wierzbowski Eversheds and Crescendo Communications. For more information please visit: <http://lscwarsaw.com>

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular injection systems is now complete and the Company is currently pursuing regulatory approval for both injection systems in the U.S. and European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.